Cited by 660Estrogen and related hormone effectsNuclear Receptors and SignalingGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Open access

Lavinsky, Robert M., Jepsen, Kristen, Heinzel, Thorsten, Torchia, Joseph, Mullen, Tina-Marie, Schiff, Rachel, Del-Rio, Alfonso Leon, Ricote, Mercedes, Ngo, Sally, Gemsch, Joslin, Hilsenbeck, Susan G., Osborne, C. Kent, Glass, Christopher K., Rosenfeld, Michael G., Rose, David W.·1998·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.95.6.2920PMC PMC19670

Open this paper in CoChat — free account

Abstract

Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain. Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, positively or negatively, by diverse signal transduction pathways. Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer. Our data suggest that N-CoR- and SMRT-containing complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.

Integrity signals

Registry

Crossref · 10.1073/pnas.95.6.2920

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230

Show all 4 references

Research works printed but not linked: 46

10.1006/scel.1994.1015 · DOI
10.1038/377397a0 · DOI
10.1038/387043a0 · DOI
10.1128/MCB.16.10.5458 · DOI
J-W Lee, H-S Choi, J Gyuris, R Brent, D D Moore Mol Endocrinol 9, 243–254 (1995).
10.1038/377454a0 · DOI
T Matkovits, S Christakos Mol Endocrinol 9, 232–242 (1995).
10.1210/mend.11.7.9939 · DOI
10.1016/0960-0760(95)00084-D · DOI
10.1038/387049a0 · DOI
10.1073/pnas.93.23.12845 · DOI
10.1016/0092-8674(95)90355-0 · DOI
10.1016/0092-8674(95)90356-9 · DOI
10.1016/S0092-8674(00)80211-1 · DOI
10.1038/38664 · DOI · Paper page
10.1126/science.8197458 · DOI
10.1126/science.270.5240.1354 · DOI
10.1016/S0092-8674(00)81118-6 · DOI · Paper page
10.1038/42652 · DOI
10.1016/S0955-0674(97)80066-X · DOI
10.1038/370226a0 · DOI
10.1101/gad.8.8.869 · DOI
10.1038/384641a0 · DOI
10.1016/S0092-8674(00)82001-2 · DOI · Paper page
10.1038/382319a0 · DOI
C K Osborne, R M Elledge, S Fuqua Sci Am 3, 32–41 (1996).
10.1007/BF00666205 · DOI
10.1002/j.1460-2075.1993.tb05756.x · DOI
D Ignar-Trowbridge, C Teng, K Ross, M G Parker, K S Korach, J McLachlan Mol Endocrinol 7, 992–998 (1993).
10.1073/pnas.90.13.6120 · DOI
10.1002/j.1460-2075.1996.tb00571.x · DOI
10.1083/jcb.119.6.1405 · DOI
10.1093/jnci/83.20.1477 · DOI
10.1093/jnci/87.10.746 · DOI
W Seol, M J Mahon, Y K Lee, D D Moore Mol Endocrinol 10, 1646–1655 (1996).
10.1210/mend.11.6.0009 · DOI
N Fujimoto, B S Katzenellenbogen Mol Endocrinol 8, 296–304 (1994).
10.1074/jbc.270.16.9535 · DOI
10.1074/jbc.271.39.24172 · DOI
10.1073/pnas.89.22.10563 · DOI
M Tzukerman, A Esty, D Santiso-Mere, P Danielian, M G Parker, R Stein, J W Pike, D P McDonnell Mol Endocrinol 8, 21–30 (1994).
10.1126/science.274.5295.2100 · DOI
10.1101/gad.11.7.835 · DOI
10.1093/jnci/53.1.283 · DOI
10.1073/pnas.94.20.10762 · DOI
10.1126/science.279.5351.703 · DOI

Sorted by citations

The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
“asp?DrugCode=1%2D3926&DrugName=TAMOXIFEN+CITRATE+ORAL&DrugType=1">tamoxifen ( Box 3 ) in patients with breast cance”
Background
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
“Thyroid hormone-resistance syndromes can be correlated with mutations in the LBD of TR b that enhance ligand-independent interactions anti N-CoR/SMRT (Yoh et al. 1997).”
BackgroundInfluentialSelf-citation
Mechanisms of Estrogen Action
Nilsson, S. V., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J. S., Andersson, G., Enmark, E., Pettersson, K., Warner, M. N., & Gustafsson, J.-Α. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 2,025
Nuclear Receptor Coregulators: Cellular and Molecular Biology
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,941
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. A. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,647
“Consistent with insufficient to exert the cell proliferating properties of es- trogen in breast cancer. vitro studies (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998), TAM-bound ERa did recruit nuclear receptor corepressors N-CoR and SMRT to theDiscussion promoters as well.”
Background
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou, J., Massarweh, S., Osborne, C., Wakeling, A., Ali, S., Weiss, H., & Schiff, R. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,236
“Blocking ERK1,2 MAPK also blocks phosphorylation of NCoR and restores its nuclear localization (26), thereby increasing its availability to bind and repress ER ( 27 ,28).”
BackgroundSelf-citation
MECHANISMS OF ENDOCRINE RESISTANCE IN BREAST CANCER
Osborne, C., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,205
Self-citation
Coactivator and corepressor complexes in nuclear receptor function
Xu, L., Glass, C. K., & Rosenfeld, M. G. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80021-5 · Cited by 909
Self-citation
Endocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature reviews. Cancer · doi:10.1038/nrc721 · Cited by 867
“Tamoxifen-bound ER interacts with NCORs, resulting in repression of its agonist activit”
Background
Estrogen receptor pathways to AP-1.
Kushner, P., Agard, D., Greene, G., Scanlan, T., Shiau, A., Uht, R., & Webb, P. (2000) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 953
“It exploits the recent and striking finding that ER can bind corepressors such as N-CoR, but only in the presence of SERMs [38,39].”
Background
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
“However, both NCoR and SMRT interact with ER when bound to the mixed agonist tamoxifen, an ER ligand that acts as an agonist or antagonist in a tissue-specific manner, and overexpression of either corepressor abolishes tamoxifen agonist activity (288).”
BackgroundInfluential
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
“For instance, in breast cancer cells, phosphorylation of Ser(118) in human ER leads to reduced interaction with the SMRT corepressor (119), whereas another laboratory has demonstrated that this posttranslational modification is required for the interaction of this receptor with the amino-terminal-specific coactivator,…”
Background
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K. C., Seitz, T., Li, S.-F., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 909
Self-citation
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
The Interplay between the Glucocorticoid Receptor and Nuclear Factor-κB or Activator Protein-1: Molecular Mechanisms for Gene Repression
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & FORMAN, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R., Bhat-Nakshatri, P., Patel, N., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 880
Estrogen signaling: a subtle balance between ER alpha and ER beta.
Matthews, J., & Gustafsson, J. (2003) · Molecular Interventions · doi:10.1124/mi.3.5.281 · Cited by 844
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne, C., Bardou, V., Hopp, T. A., Chamness, G., Hilsenbeck, S., Fuqua, S., Wong, J., Allred, D., Clark, G., & Schiff, R. (2003) · Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 831
Self-citation
Overview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688
“…it has been shown that some antagonists significantly enhance this interaction, as well as HDAC recruitment, at certain ER (cid:1) target promoters (Jackson et al., 1997; Lavinsky et al., 1998; Zhang et al., 1998; Shang et al., 2000; Yamamoto et al., 2001; Shang and Brown, 2002; Webb et al., 2003).”
Background
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
“org Clin Cancer Res; 20(7) April 1, 2014 1763”
BackgroundInfluential
Steroid hormone receptors: an update
Beato, M. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.225 · Cited by 615
“The same proteins are also implicated in SH action as it was demonstrated that overexpression of N-CoR and SMRT represses the partial agonistic activity of both ERα bound to the anti-hormone tamoxifen and of PR bound to the antagonist RU486 (Jackson et al., 1997; Lavinsky et al., 1998).”
Background
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
PPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612
“Notably, microinjection of antibodies directed against SMRT was able to relieve SMRT corepression of PPAR's activity but antibodies directed against the related nuclear receptor corepressor were ineffective [140].”
BackgroundInfluential
Ecdysone receptors and their biological actions
Riddiford, L. M., Cherbas, P., & Truman, J. W. (2000) · Vitamins & Hormones · doi:10.1016/s0083-6729(00)60016-x · Cited by 605
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein.
Baek, S. H., Ohgi, K., Rose, D., Koo, E., Glass, C., & Rosenfeld, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00809-7 · Cited by 591
Self-citation
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Arpino, G., Wiechmann, L., Osborne, C., & Schiff, R. (2008) · Endocrine reviews · doi:10.1210/er.2006-0045 · Cited by 574
Self-citation
Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development
Jepsen, K., Hermanson, O., Onami, T. M., Gleiberman, A. S., Lunyak, V. V., McEvilly, R. J., Kurokawa, R., Kumar, V., Liu, F. C., Seto, E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00064-7 · Cited by 511
“…(Neuman et al., 1995), was was performed as previously described using anti-rabbit antibodiesupregulated in the outer layers of neocortex of N-CoR2/2 to N-CoR (Heinzel et al., 1997) or anti-guinea pig antibodies to SMRTembryos identifies MAP2 as a putative target gene for (Lavinsky et al., 1998).”
BackgroundInfluentialSelf-citation
Molecular determinants of nuclear receptor-corepressor interactionPreprint
Perissi, V., Staszewski, L. M., McInerney, E. M., Kurokawa, R., Krones, A., Rose, D. W., L., L. M., Milburn, M. V., Glass, C. K., & Rosenfeld, M. G. (1999) · Genes & Development · doi:10.1101/gad.13.24.3198 · Cited by 514
“…of antagonists (Vegeto et al. 1992; Lanz and Rusconi 1994; Xu et al 1996; Jackson et al. 1997; Smith et al. 1997; Lavinsky et al. 1998; Wagner et al. 1998; Zhang et al. 1998a,b), and these interactions appear to be essential for full antagonist activity (Lavinsky et al. 1998; Norris et al. 1999).”
BackgroundSelf-citation
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui, X.-J., Schiff, R., Arpino, G., Osborne, C., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 527
Self-citation
Estrogen receptor interaction with co-activators and co-repressors☆
Klinge, C. M. (2000) · Steroids · doi:10.1016/s0039-128x(99)00107-5 · Cited by 494
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K., Gu, Z.-P., Lee, R., Zhu, Y., Skaar, T., Gomez, B. P., O'Brien, K. A., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 514
“Expression of the corepressor N-CoR is lower in TAM-stimulated MCF-7 xenografts than in wildtype xenografts (Lavinsky et al., 1998), but the functional relevance of the observation in human cancers is unclear.”
Background
Ligand-Independent Recruitment of SRC-1 to Estrogen Receptor β through Phosphorylation of Activation Function AF-1
Tremblay, A., Tremblay, G. B., Labrie, F., & Giguère, V. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80479-7 · Cited by 469
Coregulator codes of transcriptional regulation by nuclear receptors
Rosenfeld, M. G., & Glass, C. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100041200 · Cited by 509
Self-citation
Estrogen receptor phosphorylation.
Lannigan, D. (2003) · Steroids · doi:10.1016/s0039-128x(02)00110-1 · Cited by 490
“[84] Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al.”
Background
The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 437
The Epigenetics of Sex Differences in the Brain: Figure 1.
McCarthy, M. M., Auger, A. P., Bale, T. L., Vries, G. J. D., Dunn, G. A., Forger, N. G., Murray, E. K., Nugent, B. M., Schwarz, J. M., & Wilson, M. E. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3331-09.2009 · Cited by 495
“It was then found to be a corepressor molecule for androgen and estrogen receptors (Lavinsky et al., 1998; Yoon and Wong, 2006).”
Background
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 522
Selective Estrogen Receptor Modulators
Frasor, J. M., Stossi, F., Danes, J. M., Komm, B. S., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 400
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. H. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 412
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Patel, H., & Bihani, T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 531
Cellular and molecular pharmacology of antiestrogen action and resistance.
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 421
Estrogen Receptor Mutations in Human Disease
Herynk, M. H., & Fuqua, S. A. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0010 · Cited by 412
The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions
Webb, P., Nguyen, P. T., Valentine, C. D., Lopez, G. N., Kwok, G. R., McInerney, E. M., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J.-Α., Nilsson, S. V., et al. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.10.0357 · Cited by 391
Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
Paige, L. A., Christensen, D. J., Grøn, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3999 · Cited by 410
Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 375
The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function
Ricote, M., Huang, J. T., Welch, J. S., & Glass, C. K. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.5.733 · Cited by 306
Self-citation
Selective estrogen receptor modulators: structure, function, and clinical use.
Osborne, C. K., Zhao, H., & Fuqua, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3172 · Cited by 382
Self-citation
Estrogen Receptor Activation Function 1 Works by Binding p160 Coactivator Proteins
Webb, P., Nguyen, P. T., Shinsako, J., Anderson, C. M., Feng, W., Nguyen, M. P., Chen, D., Huang, S.-M., Subramanian, S., McKinerney, E., et al. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.10.0185 · Cited by 382
“Our study complements a recently published study which shows that microinjection of anti-p160 or anti-CBP antibodies block tamoxifen response in cells (HepG2) where AF-1 activity is high (62).”
Background
The histone deacetylase-3 complex contains nuclear receptor corepressors
Wen, Y.-D., Perissi, V., Staszewski, L. M., Yang, W.-M., Krones, A., Glass, C. K., Rosenfeld, M. G., & Seto, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7202 · Cited by 378
Self-citation
Phosphorylation of the Nuclear Receptor SF-1 Modulates Cofactor Recruitment
Hammer, G. D., Krylova, I., Zhang, Y., Darimont, B. D., Simpson, K., Weigel, N. L., & Ingraham, H. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80480-3 · Cited by 375
Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression
Scarpin, K. M., Graham, J., Mote, P., & Clarke, C. (2009) · Nuclear Receptor Signaling · doi:10.1621/nrs.07009 · Cited by 374
“Decreased expression of these corepressors may contribute to the tamoxifen resistance phenotype [Lavinsky et al., 1998; Smith et al., 1997].”
Nuclear Hormone Receptor Coregulators In Action: Diversity For Shared Tasks
Robyr, D., Wolffe, A. P., & Wahli, W. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.3.0411 · Cited by 385
Non-genomic actions of estrogens and their interaction with genomic actions in the brain.
Vasudevan, N., & Pfaff, D. (2008) · Frontiers in neuroendocrinology (Print) · doi:10.1016/j.yfrne.2007.08.003 · Cited by 360
Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications
Arnal, J., Lenfant, F., Métivier, R., Flouriot, G., Henrion, D., Adlanmérini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B. S., et al. (2017) · Physiological Reviews · doi:10.1152/physrev.00024.2016 · Cited by 453
Structural Insights into the Mode of Action of a Pure Antiestrogen
Pike, A. C. W., Brzozowski, A. M., Walton, J., Hubbard, R. E., Thorsell, A. G., Li, Y.-L., Gustafsson, J.-Α., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 353
Interdomain communication regulating ligand binding by PPAR-γ
Shao, D., Rangwala, S. M., Bailey, S. T., Krakow, S. L., Reginato, M. J., & Lazar, M. A. (1998) · Nature · doi:10.1038/24634 · Cited by 354
The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua, A., Bonofiglio, D., Recchia, A., Musti, A., Picard, D., Andò, S., & Maggiolini, M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0280 · Cited by 345
“In addition, an altered expression of ER coregulators has been associated with the progression of breast cancers toward a more malignant and TAM-resistant phenotype (26).”
Background
Nuclear receptor coregulators: multiple modes of modification.
Hermanson, O., Glass, C., & Rosenfeld, M. (2002) · Trends in endocrinology and metabolism · doi:10.1016/s1043-2760(01)00527-6 · Cited by 341
Self-citation
Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance
Ali, S., & Coombes, R. (2000) · Journal of mammary gland biology and neoplasia · doi:10.1023/a:1009594727358 · Cited by 336
The Role of Corepressors in Transcriptional Regulation by Nuclear Hormone Receptors
Privalsky, M. L. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.155556 · Cited by 330
Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription
Collingwood, T., Urnov, F. D., & Wolffe, A. P. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0230255 · Cited by 318
“The ER can also bind the NCoR and SMRT corepressors in the presence of antagonists such as tamoxifen and RU486 (Laherty et al. 1998, Lavinsky et al. 1998).”
A Novel Nuclear Receptor Corepressor Complex, N-CoR, Contains Components of the Mammalian SWI/SNF Complex and the Corepressor KAP-1*
Underhill, C., Qutob, M. S., Yee, S.-P., & Torchia, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007864200 · Cited by 323
Self-citation
Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre, M., & Smith, C. L. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38923-2 · Cited by 320
“Moreover, in cells in which tamoxifen is an antagonist, tamoxifen, but not estradiol, enhances ER interactions with N-CoR (Lavinsky et al., 1998).”
Influential
The Molecular Pharmacology of SERMs.
McDonnell, D. P. (1999) · Trends in endocrinology and metabolism · doi:10.1016/s1043-2760(99)00177-0 · Cited by 317
A Tissue-Specific Coactivator of Steroid Receptors, Identified in a Functional Genetic Screen
Knutti, D., Kaul, A., & Kralli, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2411-2422.2000 · Cited by 286
“Among them, corepressors such as SMRT and NcoR bind to receptors in the absence of hormone or the presence of an antagonist ligand, connect the receptors to histone deacetylases, and promote the silencing of neighboring promoters (9, 21, 23, 35, 51).”
Background
Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer
Katzenellenbogen, B., & Katzenellenbogen, J. (2000) · Breast Cancer Research · doi:10.1186/bcr78 · Cited by 313
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Maïo, M. D., Maio, E. D., Luca, A. D., Matteis, A. D., Giordano, A., & Perrone, F. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
“In addition, it has been shown that tamoxifen interacts with co-repressors when bound to ER, and that this mechanism is involved in the suppression of transcription (Lavinsky et al .”
Background
Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Hall, J. M. (2005) · Molecular Interventions · doi:10.1124/mi.5.6.7 · Cited by 291
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E. A., & Jordan, V. C. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527623297.ch5 · Cited by 230
Estrogen Receptor Binding to DNA Is Not Required for Its Activity through the Nonclassical AP1 Pathway*
Jakacka, M., Ito, M., Weiss, J., Chien, P.-Y., Gehm, B. D., & Jameson, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008384200 · Cited by 299
Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle
Seto, A. G., Zaug, A. J., Sobel, S. G., Wolin, S. L., & Cech, T. R. (1999) · Nature · doi:10.1038/43694 · Cited by 281
Signal-specific co-activator domain requirements for Pit-1 activation
Xu, L., Lavinsky, R. M., Dasen, J. S., Flynn, S. E., McInerney, E. M., Mullen, T.-M., Heinzel, T., Szeto, D. P., Korzus, E., Kurokawa, R., et al. (1998) · Nature · doi:10.1038/26270 · Cited by 284
“The observation that 4- trans -hydroxytamoxifen (TOT), an antagonist of the oestrogen receptor, but not the agonist 17-β-oestradiol, induces N-CoR interaction with the oestrogen recepto”
BackgroundSelf-citation
Transcriptional repression by nuclear hormone receptors.
Hu, X., & Lazar, M. (2000) · Trends in endocrinology and metabolism · doi:10.1016/s1043-2760(99)00215-5 · Cited by 297
Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor.
Htun, H., Holth, L. T., Walker, D., Davie, J., & Hager, G. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.2.471 · Cited by 297
LIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS
Nettles, K. W., & Greene, G. L. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.154710 · Cited by 268
Phosphorylation of Steroid Receptor Coactivator-1
Rowan, B. G., Weigel, N. L., & O’Malley, B. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4475 · Cited by 267
Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length
Irvine, R. A. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.267 · Cited by 263
“Recently, however, it was revealed that p160 coactivators interact with the NTDs of the estrogen receptor (ER) (35, 36 ), the progesterone receptor (PR) (37) and the AR (38) in addition to binding to their respective LBDs.”
Background
Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription
Dilworth, F. J., & Chambon, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204329 · Cited by 269
“…ligands to either ER or PR permit the binding of the homodimers to their respective response elements in vivo without inducing an active AF-2, further demonstrating that this activation function does not play a role in receptor binding to the template (Lavinsky et al., 1998; Smith et al., 1997).”
Background
The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription
Alen, P., Claessens, F., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6085 · Cited by 268
Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway
Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., García-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 262
“Based on genetic analyses, N-CoR proves to be required for the inhibitory function of estrogen receptor (ER) antagonists (SERMs) (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998; reviewed in Glass and Rosenfeld, 2000; McKenna and O’Malley, 2002).”
Self-citation
The PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor α
Kressler, D., Schreiber, S., Knutti, D., & Kralli, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201134200 · Cited by 248
8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein
Rowan, B. G., Garrison, N., Weigel, N. L., & O’Malley, B. W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8720-8730.2000 · Cited by 244
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
García-Becerra, R., Santos, N. D., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 261
“In a xenograft model for human breast cancer, NCoR levels decreased in the tumors that acquired resistance to tamoxifen [230].”
Background
A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis
Gurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T. N., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J. W. R., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5754 · Cited by 263
The pleiotropic functions of peroxisome proliferator-activated receptor γ
Debril, M.-B., Renaud, J., Fajas, L., & Auwerx, J. H. (2000) · Journal of Molecular Medicine · doi:10.1007/s001090000145 · Cited by 222
The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor γ Transcriptional Activity and Repress 3T3-L1 Adipogenesis
Yu, C., Markan, K. R., Temple, K. A., Deplewski, D., Brady, M., & Cohen, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409468200 · Cited by 238
Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis
Fajas, L., Debril, M.-B., & Auwerx, J. H. (2001) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0270001 · Cited by 232
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α
Kawai, H., Li, H.-C., Avraham, S., Jiang, S.-X., & Avraham, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11403 · Cited by 241
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
Zheng, L., Annab, L., Afshari, C., Lee, W.-H., & Boyer, T. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.171174298 · Cited by 241
Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state
Green, K. A., & Carroll, J. S. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2211 · Cited by 221
“, and NCOR1 levels are reduced in mouse models of tamoxifen resistanc”
Background
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression
Bhardwaj, P., Au, C. C., Benito-Martin, A., Ladumor, H., Oshchepkova, S., Moges, R., & Brown, K. A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.002 · Cited by 233
Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles
Vasudevan, N., & Pfaff, D. W. (2007) · Endocrine Reviews · doi:10.1210/er.2005-0021 · Cited by 231
“This is possibly because phosphorylation of nuclear receptors appears to enhance interaction with coactivators (188).”
Background
SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors.
Laherty, C. D., Billin, A., Lavinsky, R. M., Yochum, G., Bush, A. C., Sun, J.-M., Mullen, T., Davie, J. R., Rose, D., Glass, C. K., et al. (1998) · Molecules and Cells · doi:10.1016/s1097-2765(00)80111-2 · Cited by 231
Self-citation
HDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 221
“In other examples, it is the antagonist-bound receptor that interacts with N-CoR/ SMRT to repress transcription (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998).”
Prolactin modulation of immune and inflammatory responses.
Yu-Lee, L. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.435 · Cited by 222
“, by changing an estrogen antagonist into an agonist) (Lavinsky et al., 1998; McDonnell, 1999).”
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
Gelman, L., Fruchart, J., & Auwerx, J. H. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050345 · Cited by 199

Authors: Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., & Rose, D. W.
Affiliations: Howard Hughes Medical Institute (US)
Howard Hughes Medical Institute, Cellular and Molecular Medicine, Whittier Diabetes Program, and UCSD Graduate Program in Biology, Department and School of Medicine, University of California at San Diego, La Jolla, CA 92093-0648; and Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284-7884
Corresponding author: Rose, David W.
ORCID: Jepsen, Kristen
Heinzel, Thorsten
Torchia, Joseph
Mullen, Tina-Marie
Schiff, Rachel
Ricote, Mercedes
Hilsenbeck, Susan G.
Osborne, C. Kent
Glass, Christopher K.
Rosenfeld, Michael G.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 1998-03-17
Volume: 95
Issue: 6
Pages: 2920-2925
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.95.6.2920
PMC: PMC19670
OpenAlex: W2128003724
Cited by: 660
References: 52
Citations by year: 2026: 5 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 10 · 2021: 6 · 2020: 10 · 2019: 13 · 2018: 10 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 13 · 2013: 12 · 2012: 20
FWCI: 30.37
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Science Foundation
Howard Hughes Medical Institute
American Diabetes Association
National Institutes of Health
National Cancer Institute (P30CA 54174, P30CA054174, P50 CA58183, P50CA058183)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: nuclear receptor corepressor, SMRT, signaling pathways, retinoic acid receptor, estrogen receptor, tamoxifen resistance, breast cancer, transcriptional repression, ligand-dependent transcription, CREB-binding protein, coactivator complexes
MeSH terms: Animals, Breast Neoplasms, Disease Models, Animal, DNA-Binding Proteins, Drug Resistance, Estrogen Antagonists, Gene Expression Regulation, Humans, Models, Biological, Nuclear Proteins, Protein Binding, Protein Kinases, Receptors, Estrogen, Repressor Proteins, Tamoxifen, Signal Transduction, Genes, Reporter, Receptors, Retinoic Acid, Mice, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Co-Repressor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks